- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 21, Issue 26, 2014
Current Medicinal Chemistry - Volume 21, Issue 26, 2014
Volume 21, Issue 26, 2014
-
-
Editorial (Thematic Issue: Signalling Pathways in Anti-cancer Drug Resistance)
Authors: Chen Chen, Jiezhong Chen and Kong-Nan ZhaoCancer is a common disease responsible for a significant proportion of human mortality. There are totally more than 200 types of cancers. The most common ones are lung, prostate, breast and colorectal cancers. The severity of cancer as a health problem is evidenced by a statistical analysis for the cancer incidence and mortality. It has been estimated that total cancer incidences worldwide are 12.7 million and total c Read More
-
-
-
Targeting Platinum Resistant Disease in Ovarian Cancer
Authors: S.L. Morgan, J.E. Medina, M.M. Taylor and D.M. DinulescuOvarian cancer is an extremely aggressive disease in which the vast majority of patients face a very poor prognosis. Although most patients initially respond to current chemotherapeutic regimens that include a combination of platinum- based therapy (cisplatin/carboplatin) and paclitaxel, the vast majority of them quickly relapse and develop increased resistance to available treatments. Thus, intrinsic and acquired chemothera Read More
-
-
-
HIF-1 Signaling in Drug Resistance to Chemotherapy
Authors: N.A. Warfel and W.S. El-DeiryActivation of hypoxia-inducible factor 1 (HIF-1) signaling is observed in a broad range of human cancers due to tumor hypoxia and epigenetic mechanisms. HIF-1 activation leads to the transcription of a plethora of target genes that promote physiological changes associated with therapeutic resistance, including the inhibition of apoptosis and senescence and the activation of drug efflux and cellular metabolism. As Read More
-
-
-
Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Authors: Hongping Xia and Kam M. HuiDrug resistance is one of the major reasons for the failure of cancer therapies. Although our understanding of resistance to targeted cancer drugs remains incomplete, new and more creative approaches are being exploited to intercept this phenomenon. Considerable advances have been made in our understanding that cancer drug resistance can be caused by alterations of drug efflux, increases in drug metabolism, muta Read More
-
-
-
IL-6 Activated JAK/STAT3 Pathway and Sensitivity to Hsp90 Inhibitors in Multiple Myeloma
Authors: I. Kolosenko, D. Grander and K.P. TammModern anti-cancer treatment involves targeted therapy that aims at inactivating particular oncoproteins or signaling pathways in a cancer-type-specific manner. A number of potent targeted therapies affecting oncogenic kinases or receptor tyrosine kinases have revolutionized anti-cancer treatment. These drugs inactivate signaling pathways that cancer cells depend on and therefore inhibit their proliferation and survival. Read More
-
-
-
Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
Authors: K.D. Tang and Ming-Tat LingThe phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway is one of the most frequently activated signaling pathways in prostate cancer cells, and loss of the tumor suppressor PTEN and amplification of PIK3CA are the two most commonly detected mechanisms for the activation of these pathways. Aberrant activation of PI3K/Akt/mTOR has been implicated not only in the survival and metastasis of prostate cancer cells but Read More
-
-
-
Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Authors: Jianghong Wu, Jiezhong Chen, Lifang Zhang, Paul P. Masci and Kong-Nan ZhaoEpidemiological surveys and molecular studies have indicated that infection of human papillomavirus (HPV)itself is necessary but insufficient for completing transformation of the human epithelial cells in vivo to lead to different cancers. Mounting evidence exists that HPV E6/E7 oncoproteins indeed alter the cellular and molecular events in their transformed cells to induce cancers through a phosphatidylinositol 3-kinase (PI3K) Read More
-
-
-
Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Authors: Jiezhong Chen, Kong-Nan Zhao, Rui Li, Renfu Shao and Chen ChenEndometrial cancer is the third most common cancer in women. Endometrial carcinomas (EC) are clinic histologically classified into two types. Type I tumours, which account for 80% of ECs, are estrogen-dependent and are low grade. Type II tumours are more aggressive with invasion into myometrium. Recently a new classification for endometrial cancer has been proposed based on molecular markers. Whether this classif Read More
-
-
-
DNA Binding Mode of Transition Metal Complexes, A Relationship to Tumor Cell Toxicity
Authors: M. Ashfaq, T. Najam, S.S.A. Shah, M.M. Ahmad, S. Shaheen, R. Tabassum and G. RiveraTransition metal-based compounds constitute a distinct class of chemotherapeutics extensively used in the clinic as antitumor and antiviral agents. However, drug resistance and side effects of established antitumor metallodrugs such as cisplatin [cis-diamminedichloroplatinum(II)] and its analogues, carboplatin and oxaliplatin, have limited their clinical utility. These limitations have prompted a search for more effective and Read More
-
-
-
Salvianolic Acid B Inhibits Atherogenesis of Vascular Cells through Induction of Nrf2-dependent Heme Oxygenase-1
Authors: Hyun Jung Lee, MiRanSeo and Eun Jig LeeAims: Salvianolic acid B (Sal B), one of the most active components of Danshen extracts, has beneficial roles in the prevention and treatment of cardiovascular diseases. However, the precise mechanism by which Sal B exerts its effects on vascular cells is unclear. We aimed to elucidate the effects of Sal B on vascular cells and the underlying mechanisms. Methods and Results: Treatment of vascular smooth muscle cells with Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 20 (2013)
-
Volume 19 (2012)
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
